{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T21:14:00Z","timestamp":1778793240629,"version":"3.51.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,9,12]],"date-time":"2016-09-12T00:00:00Z","timestamp":1473638400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"supported by the Ed and Joey Story Endowed Chair"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s10620-016-4294-z","type":"journal-article","created":{"date-parts":[[2016,9,12]],"date-time":"2016-09-12T06:14:54Z","timestamp":1473660894000},"page":"3270-3277","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Impact of Low Immunoglobulin G Levels on Disease Outcomes in Patients with Inflammatory Bowel Diseases"],"prefix":"10.1007","volume":"61","author":[{"given":"Nicholas","family":"Horton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianrui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Philpott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ari","family":"Garber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Paul","family":"Achkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Brzezinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bret A.","family":"Lashner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,9,12]]},"reference":[{"key":"4294_CR1","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1159\/000354685","volume":"31","author":"S Foersch","year":"2013","unstructured":"Foersch S, Waldner MJ, Neurath MF. Innate and adaptive immunity in inflammatory bowel diseases. Dig Dis. 2013;31:317\u2013320.","journal-title":"Dig Dis"},{"key":"4294_CR2","first-page":"3178","volume":"17","author":"B Siegmund","year":"2011","unstructured":"Siegmund B, Zeitz M. Innate and adaptive immunity in inflammatory bowel disease. World J Gastroenterol. 2011;17:3178\u20133183.","journal-title":"World J Gastroenterol"},{"key":"4294_CR3","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/ajg.2010.78","volume":"105","author":"S Schreiber","year":"2010","unstructured":"Schreiber S, Colombel JF, Bloomfield R, et al. Increased response and remission rates in short-duration Crohn\u2019s disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol. 2010;105:1574\u20131582.","journal-title":"Am J Gastroenterol"},{"key":"4294_CR4","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","volume":"130","author":"SB Hanauer","year":"2006","unstructured":"Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn\u2019s disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323\u2013333.","journal-title":"Gastroenterology"},{"key":"4294_CR5","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","volume":"146","author":"WJ Sandborn","year":"2007","unstructured":"Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146:829\u2013838.","journal-title":"Ann Intern Med"},{"key":"4294_CR6","first-page":"137","volume":"72","author":"CA Armstrong-Esther","year":"1976","unstructured":"Armstrong-Esther CA, Williams A. Serum immunoglobulin levels in ulcerative colitis: an investigation. Nurs Times. 1976;72:137\u2013139.","journal-title":"Nurs Times."},{"key":"4294_CR7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1136\/gut.15.3.213","volume":"15","author":"PM Bolton","year":"1974","unstructured":"Bolton PM, James SL, Newcombe RG, Whitehead RH, Hughes LE. The immune competence of patients with inflammatory bowel disease. Gut. 1974;15:213\u2013219.","journal-title":"Gut"},{"key":"4294_CR8","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.0954-6820.1969.tb01444.x","volume":"186","author":"B Weeke","year":"1969","unstructured":"Weeke B, Bendixen G. Serum immunoglobulins and organ-specific, cellular hypersensitivity in ulcerative colitis and Crohn\u2019s disease. Acta Med Scand. 1969;186:87\u201391.","journal-title":"Acta Med Scand."},{"key":"4294_CR9","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/gut.12.4.297","volume":"12","author":"B Weeke","year":"1971","unstructured":"Weeke B, Jarnum S. Serum concentration of 19 serum proteins in Crohn\u2019s disease and ulcerative colitis. Gut. 1971;12:297\u2013302.","journal-title":"Gut"},{"key":"4294_CR10","first-page":"283","volume":"46","author":"MB Pepys","year":"1977","unstructured":"Pepys MB, Druguet M, Klass HJ, Dash AC, Mirjah DD, Petrie A. Immunological studies in inflammatory bowel disease. Ciba Found Symp. 1977;46:283\u2013304.","journal-title":"Ciba Found Symp"},{"key":"4294_CR11","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1080\/00365521.1975.12097008","volume":"10","author":"IL Marner","year":"1975","unstructured":"Marner IL, Friborg S, Simonsen E. Disease activity and serum proteins in ulcerative colitis. Immunochemical quantitation. Scand J Gastroenterol. 1975;10:537\u2013544.","journal-title":"Scand J Gastroenterol"},{"key":"4294_CR12","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/gastro\/gou082","volume":"3","author":"T Rai","year":"2015","unstructured":"Rai T, Wu X, Shen B. Frequency and risk factors of low immunoglobulin levels in patients with inflammatory bowel disease. Gastroenterol Rep (Oxf).. 2015;3:115\u2013121.","journal-title":"Gastroenterol Rep (Oxf)."},{"key":"4294_CR13","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1097\/MIB.0000000000000456","volume":"21","author":"SA Merkley","year":"2015","unstructured":"Merkley SA, Beaulieu DB, Horst S, Duley C, et al. Use of intravenous immunoglobulin for patients with inflammatory bowel disease with contraindications or who are unresponsive to conventional treatments. Inflamm Bowel Dis. 2015;21:1854\u20131859.","journal-title":"Inflamm Bowel Dis"},{"key":"4294_CR14","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","volume":"317","author":"KW Schroeder","year":"1987","unstructured":"Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625\u20131629.","journal-title":"N Engl J Med"},{"key":"4294_CR15","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","volume":"1","author":"RF Harvey","year":"1980","unstructured":"Harvey RF, Bradshaw JM. A simple index of Crohn\u2019s-disease activity. Lancet. 1980;1:514.","journal-title":"Lancet"},{"key":"4294_CR16","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/gut.2005.082909","volume":"55","author":"J Satsangi","year":"2006","unstructured":"Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749\u2013753.","journal-title":"Gut"},{"key":"4294_CR17","doi-asserted-by":"crossref","first-page":"e100324","DOI":"10.1371\/journal.pone.0100324","volume":"9","author":"SS Duraisingham","year":"2014","unstructured":"Duraisingham SS, Buckland M, Dempster J, Lorenzo L, Grigoriadou S, Longhurst HJ. Primary vs. secondary antibody deficiency: clinical features and infection outcomes of immunoglobulin replacement. PLoS ONE. 2014;9:e100324.","journal-title":"PLoS ONE"},{"key":"4294_CR18","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.healun.2007.09.010","volume":"26","author":"MH Yamani","year":"2007","unstructured":"Yamani MH, Narayan SB, Haire C, Hobbs R. Hypogammaglobulinemia in heart failure patients: prevalence and impact on infectious outcomes. J Heart Lung Transplant. 2007;26:1350\u20131351.","journal-title":"J Heart Lung Transplant"},{"key":"4294_CR19","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/00042737-199606000-00016","volume":"8","author":"U Muller-Ladner","year":"1996","unstructured":"Muller-Ladner U, Gross V, Andus T, et al. Distinct patterns of immunoglobulin classes and IgG subclasses of autoantibodies in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 1996;8:579\u2013584.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"4294_CR20","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3109\/00365529509093235","volume":"30","author":"EK Philipsen","year":"1995","unstructured":"Philipsen EK, Bondesen S, Andersen J, Larsen S. Serum immunoglobulin G subclasses in patients with ulcerative colitis and Crohn\u2019s disease of different disease activities. Scand J Gastroenterol. 1995;30:50\u201353.","journal-title":"Scand J Gastroenterol"},{"key":"4294_CR21","first-page":"1720","volume":"46","author":"I Gouni-Berthold","year":"1999","unstructured":"Gouni-Berthold I, Baumeister B, Berthold HK, Schmidt C. Immunoglobulins and IgG subclasses in patients with inflammatory bowel disease. Hepatogastroenterology. 1999;46:1720\u20131723.","journal-title":"Hepatogastroenterology"},{"key":"4294_CR22","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.autrev.2012.04.006","volume":"12","author":"M Rogosnitzky","year":"2012","unstructured":"Rogosnitzky M, Danks R, Holt D. Intravenous immunoglobulin for the treatment of Crohn\u2019s disease. Autoimmun Rev. 2012;12:275\u2013280.","journal-title":"Autoimmun Rev"},{"key":"4294_CR23","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1055\/s-2007-963098","volume":"45","author":"A Chrissafidou","year":"2007","unstructured":"Chrissafidou A, Malek M, Musch E. Experimental study on the use of intravenous immunoglobulin (IVIg) in patients with steroid-resistant Crohn\u2019s disease. Z Gastroenterol. 2007;45:605\u2013608.","journal-title":"Z Gastroenterol"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-016-4294-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-016-4294-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-016-4294-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T04:14:28Z","timestamp":1657253668000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-016-4294-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,12]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["4294"],"URL":"https:\/\/doi.org\/10.1007\/s10620-016-4294-z","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,12]]}}}